MAZE — Maze Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.87bn
- $1.49bn
- $167.50m
- 64
- 23
- 94
- 64
Annual income statement for Maze Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 168 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 113 | 98.6 | 110 |
| Operating Profit | -113 | -98.6 | 57.6 |
| Total Net Non Operating Interest Income / Expense | |||
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -115 | -100 | 53.4 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -115 | -100 | 52.2 |
| Equity in Affiliates | |||
| Net Income Before Extraordinary Items | |||
| Net Income | -115 | -100 | 18.4 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -115 | -100 | 3.4 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -2.57 | -2.29 | 0.078 |
| Dividends per Share |